Related Experiment Videos
A randomized placebo-controlled double-blind study of danazol in hemophilia A
J Mehta1, S Singhal, M V Kamath
1Dr. J.C. Patel Department of Hematology, KEM Hospital, Bombay, India.
Insights
Danazol treatment increased Factor VIII:C levels in patients with hemophilia A. This therapy showed promise for selected individuals, reducing bleeding episodes and the need for cryoprecipitate transfusions.
Area of Science:
- Hematology
- Pharmacology
Background:
- Hemophilia A is a genetic bleeding disorder characterized by deficient Factor VIII:C.
- Current treatments primarily involve factor replacement therapy, which can be burdensome.
Purpose of the Study:
- To evaluate the efficacy of danazol in increasing Factor VIII:C levels in patients with hemophilia A.
- To assess the impact of danazol on bleeding episodes and cryoprecipitate requirements.
Main Methods:
- A randomized, double-blind, placebo-controlled crossover trial was conducted.
- Nineteen patients with hemophilia A received danazol for 3 months at age-adjusted doses.
- Factor VIII:C levels, bleeding episodes, and cryoprecipitate usage were monitored.
Main Results:
- Danazol treatment significantly increased mean Factor VIII:C levels from 8.3% to 15.3% (p = 0.02).
- Six patients (31.6%) experienced a 1.36- to 2.87-fold elevation in Factor VIII:C.
- Responders showed reduced bleeding and cryoprecipitate needs; no adverse effects were reported.
Conclusions:
- Danazol demonstrates potential as a therapeutic agent to elevate Factor VIII:C levels in selected hemophilia A patients.
- This approach may offer an alternative or adjunct to traditional factor replacement therapy.
- Further research is warranted to identify optimal patient selection criteria and long-term outcomes.
Abstract:
A randomized double-blind placebo-controlled crossover trial of danazol was carried out in 19 cases of hemophilia A. Danazol was given for 3 months at a dose of 150 mg/day to patients under 15 years of age, and 300 mg/day to older patients. The basal factor VIII:C level was 8.3 +/- 5.6% (mean +/- SD), and after 3 months of danazol treatment was 15.3 +/- 11.0% (p = 0.02). Six patients (basal factor VIII:C 2-22%) showed a 1.36- to 2.87-fold elevation of factor VIII:C levels after danazol. 0/2, 1/4 and 5/13 cases of severe, moderate and mild disease, respectively, responded. Decreases in the number of bleeding episodes and cryoprecipitate requirement were seen in the responders. No adverse reactions to danazol were encountered. Danazol appears to raise the factor VIII:C levels in selected cases of hemophilia A.